Karnofsky Performance Status Scale
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
The Karnofsky Performance Status Scale calculates staging malignant disease, estimating overall survival, and assessing chemotherapy tolerability. Key inputs include performance status. Scores guide adjusting systemic antineoplastic regimens, planning supportive palliative measures, or targeted monitoring. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Determines patient's ability to tolerate therapies in serious illness, specifically for chemotherapy. This validated functional status scale ranges from 100% (normal, no evidence of disease) to 0% (death) and correlates with treatment tolerance, survival, and quality of life in cancer patients.
Clinical Indication
The Karnofsky Performance Status Scale is indicated for bedside clinical practice to support Determines patient's ability to tolerate therapies in serious illness, specifically for chemotherapy. This validated functional status scale ranges from 100% (normal, no evidence of disease) to 0% (death) and correlates with treatment tolerance, survival, and quality of life in cancer patients.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.
Limitations & Contraindications
Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care.
Clinical Pearls & Action Plan
Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival. Guideline pearl: Widely used in oncology for treatment eligibility, clinical trial enrollment, and prognosis assessment.
Direct assessment using standardized 11-point scale (0, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100%) based on functional capabilities
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| performance_status | integer | Yes | Karnofsky Performance Status percentage based on patient's functional capabilities and symptoms. Higher scores indicate better functional status and greater ability to tolerate treatment.(percentage) |
Evidence-Based References (EBM)
- Karnofsky DA, Abelmann WH, Craver LF, Burchenal JH. The use of the nitrogen mustards in the palliative treatment of carcinoma. With particular reference to bronchogenic carcinoma. Cancer. 1948;1(4):634-656.
- Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM, editor. Evaluation of chemotherapeutic agents. New York: Columbia University Press; 1949. p. 196.
- Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited reliability, validity, and guidelines. J Clin Oncol. 1984;2(3):187-193.
- Yates JW, Chalmer B, McKegney FP. Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer. 1980;45(8):2220-2224.